The company was set up in 2012 with the aim of using the very latest techniques and technologies to produce a variety of recombinant clotting factor products, starting with a Factor VIII product (rFVIII). They hope that their new Chinese Hamster Ovary cell line will express the molecule far more efficiently than other lines and that new manufacturing processes will keep costs down. Their aim is to produce a product which can increase supply to emerging markets such as Central and Eastern Europe and drastically improve patient care.
While they are getting very encouraging results their product will have to pass a range of toxicology tests and clinical trials before it comes to market. However, if everything runs smoothly then there could be a new Scottish product on the market by the time that the World Federation of Hemophilia (WFH) Congress comes to Glasgow in 2018.
Although the Scottish Government is supporting the venture through Scottish Enterprise they tell us that securing all the necessary investment is a much bigger challenge than overcoming the technological obstacles. So if you happen to have a few million pounds burning a hole in your pocket they’d be delighted to hear from you.